16
Mar
2015
The Top 20 Early-Stage Biotech Investors (And 2 Resuscitated By the Boom)
It takes brains, nerves, absurd self-confidence, and above all, patience, to invest in early-stage biotech companies. In a world fixated on quick and easy returns, these venture investors—from the 15 or 20 firms that survived the Great Recession—are strange birds. But now that boom days are here, some of them are making big bucks, and fast. Lately, I’ve been wondering:... Read More
Share:
9
Mar
2015
2015 Power Rankings: Biotech Investment Banks
Which banks have the most power in biotech? You could just flip to the bottom of the press release on AbbVie’s $21 billion acquisition of Pharmacyclics last week. Morgan Stanley, Centerview Partners, and JP Morgan cashed in big-time on that megadeal. But there are a lot of banks making hay while the sun is shining in biotech, in their own... Read More
Share:
23
Feb
2015
Who Is Poised To Go Public in 2015, and Who Isn’t?
This is the greatest bull market ever for biotech IPOs, which everyone reading this surely knows. If Dr. Seuss were around, he’d ask something like: “How long can it go? Nobody knows.” Renaissance Capital counted 102 healthcare IPOs last year, more than one-third of all the new stock offerings in the U.S. An infusion of more than $9 billion flowed to... Read More
Share:
